TransUnion 8-K Filing Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TransUnion on December 17, 2021. The report details a significant corporate transaction completed on the same date involving the divestiture of a specific business segment.
Key Financial Metrics
The filing discloses a transaction value of $1.735 billion in cash. This amount is subject to customary purchase price adjustments. The filing does not provide specific data on overall revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
On December 17, 2021, TransUnion LLC, a subsidiary of TransUnion, completed the divestiture of TransUnion Healthcare, Inc. This transaction included the healthcare revenue cycle management and data analytics insights business. The sale represents a material change to the company's operational structure and asset base.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the completion of the divestiture. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the final purchase price after customary adjustments to the initial $1.735 billion.
- Review subsequent filings (e.g., 10-K or 10-Q) for the impact of this divestiture on consolidated revenue and earnings.
- Confirm the allocation of the purchase price and any resulting gain or loss on the sale.
- Assess how the removal of the healthcare segment affects the company's strategic focus and future growth projections.